Current understanding of biochemical markers in heart failure

Medical Science Monitor

Volumn 12, Issue 11, 2006, Pages

  Sato, Yukihito ^a   Miyamoto, Tadashi ^a   Taniguchi, Ryoji ^b   Nishio, Yukiko ^b   Kita, Toru ^b   Fujiwara, Hisayoshi ^a   Takatsu, Yoshiki ^a  

^a HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Biochemical markers; Brain natriuretic peptide; Heart failure; Risk stratification; Troponin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CELL ADHESION MOLECULE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; FATTY ACID BINDING PROTEIN; IBOPAMINE; MYOSIN; NORADRENALIN; RENIN; TROPONIN;

CELL DAMAGE; HEART FAILURE; HUMAN; MORBIDITY; MORTALITY; MUSCLE CELL; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW;

BIOLOGICAL MARKERS; COLLAGEN; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; OBSERVER VARIATION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK; TREATMENT OUTCOME; TROPONIN;

EID: 33750959301     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (191)

1. Jessup M, Brozena S: Heart Failure. N Engl J Med, 2003; 348: 2007-18
2. McMurray JJV, Pfeffer MA: Heart failure. Lancet, 2005; 365: 1877-89
3. Esler M, Kaye D, Lambert G et al: Adrenergic nervous system in heart failure. Am J Cardiol, 1997; 80(11A): 7L-14L
4. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med, 1999; 341: 577-85
5. Bristow MR: β-adrenergic receptor blockade in chronic heart failure. Circulation, 2000; 101: 558-69
6. Lohse MJ, Engelhardt S, Eschenhagen T: What is the role of β-adrenergic signaling in heart failure? Circ Res, 2003; 93: 896-906
7. Kaye DM, Lambert GW, Lefkovits J et al: Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol, 1994; 23: 570-78
8. Cohn JN, Levine B, Olivari MT et al: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med, 1984; 311: 819-23
9. Francis GS, Cohn JN, Johnson G et al: Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation, 1993; 87(Suppl.VI): VI-40-VI-48
10. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation, 1990; 82: 1730-36
11. Francis GS, Benedict C, Johnstone DE et al: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation, 1990; 82: 1724-29
12. Varagic J, Frohlich ED: Local cardiac renin-angiotensin system: Hypertension and cardiac failure. J Mol Cell Cardiol, 2002; 34: 1435-42
13. Chatterjee K: Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol, 2005; 95(Suppl.): 8B-13B
14. Weber KT: Aldosterone in congestive heart failure. N Engl J Med, 2001; 345: 1689-97
15. Cohn JN, Johnson GR, Shabetai R et al: Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation, 1993; 87(Supppl.VI): VI-5-VI-16
16. Mann DL: Inflammatory mediators and the failing heart. Past, present, and foreseeable future. Circ Res, 2002; 91: 988-98
17. Torre-Amione G: Immune activation in chronic heart failure. Am J Cardiol, 2005; 95(Suppl.): 3C-8C
18. Rauchhaus M, Doehner W, Francis DP et al: Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation, 2000; 102: 3060-67
19. Deswal A, Peterson NJ, Feldman AM et al: Cytokines and cytokine receptors in advanced heart failure. An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation, 2001; 103: 2055-59
20. Weinberg EO, Shimpo M, Hurwitz S et al: Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation, 2003; 107: 721-26
21. Baumann H, Gauldie J: Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med, 1990; 7: 147-59
22. Anand IS, Latini R, Florea VG et al: C-reactive protein in heart failure. Prognostic value and the effect of Valsartan. Circulation, 2005; 112: 1428-34
23. Haber HL, Leavy JA, Kessler PD et al: The erythrocyte sedimentation rate in congestive heart failure. N Engl J Med, 1991; 324: 353-58
24. Sharma R, Rauchhaus M, Ponikowski PP et al: The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol, 2000; 36: 523-28
25. Pischon T, Girman CJ, Hotamisligil GS et al: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 2004; 291: 1730-37
26. Kistorp C, Faber J, Galatius S et al: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation, 2005; 112: 1756-62
27. Yang WS, Lee WJ, Funahashi T et al: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab, 2001; 86: 3815-19
28. Devaux B, Scholz D, Hirche A et al: Upregulation of cell adhesion melecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J, 1997; 18: 470-79
29. Tsutamoto T, Hisanaga T, Fukai D et al: Prognostic value of plasma soluble intercellular adhesion moleculae-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol, 1995; 76: 803-8
30. Yin WH, Chen JW, Jen HL et al: The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail, 2003; 5: 507-16
31. Adams KF, Mathur VS, Gheorghiade M, Hill C: B-type natriuretic peptide: From bench to bedside. Am Heart J, 2003; 145: S34-46
32. Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet, 2003; 362: 316-22
33. Maisel A: Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. Clin Cornerstone, 2005; 7: S7-17
34. Cowie MR, Struthers AD, Wood DA et al: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet, 1997; 350: 1347-51
35. Tsutamoto T, Wada A, Maeda K et al: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain natriuretic peptide in patients with chronic symptomatic left ventricular dysfunction. Circulation, 1997; 96: 509-16
36. Hartmann F, Packer M, Coats AJS et al: Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure. A substudy of the carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Circulation, 2004; 110: 1780-86
37. Bettencourt P, Azevedo A, Pimenta J et al: N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation, 2004; 110: 2168-74
38. Givertz MM, Colucci WS: New targets for heart failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet, 1998; 352(Suppl.1): 34-38
39. Teerlink JR: Reversal of left ventricular remodeling: Role of the endothelin pathway. J Card Fail, 2002; 8: S494-99
40. Pousset F, Isnard R, Lechat P et al: Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J, 1997; 18: 254-58
41. Hulsmann M, Stanek B, Frey B et al: Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol, 1998; 32: 1695-700
42. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol, 2000; 35: 569-82
43. Sutton MG, Sharpe N: Left ventricular remodeling after myocardial infarction. pathophysiology and therapy. Circulation, 2000; 101: 2981-88
44. Teiger E, Than VD, Richard L et al: Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest, 1996; 97: 2891-97
45. Mann DL, Kent RL, Parsons B, Cooper G: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation, 1992; 85: 790-804
46. Tan LB, Jalil JE, Pick R et al: Cardiac myocyte necrosis induced by angiotensin II. Circ Res, 1991; 69: 1185-95
47. Kajstura J, Cigola E, Malhotra A et al: Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol, 1997; 29: 859-70
48. Krown KA, Page MT, Nguyen C et al: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest, 1996; 98: 2854-65
49. Mann DL. Bristow MR: Mechanisms and models in heart failure. The biochemical model and beyond. Circulation, 2005; 111: 2837-49
50. Nadal-Ginard B, Kajstura J, Leri A, Anversa P: Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res, 2003; 92: 139-50
51. Nian M, Lee P, Khaper N, Liu P: Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res, 2004; 94: 1543-53
52. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol, 2000; 36: 959-69
53. Sato Y, Yamada T, Taniguchi R et al: Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation, 2001; 103: 369-74
54. Perna ER, Macin SM, Canella JP et al: High levels of troponin T are associated with ventricular remodeling and adverse in-hospital outcome in heart failure. Med Sci Monit, 2004; 10(3): CR90-95
55. Horwich TB, Patel J, MacLellan WR, Fonarow GC: Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation, 2003; 108: 833-38
56. Anand IS, Latini R, Kuskowski M et al: Cardiac troponin T in heart failure: Results from Val-HeFT. J Am Coll Cardiol, 2006; 47(Suppl.A): 66A (abstract)
57. Nishio Y, Sato Y, Shizuta S et al: Risk prediction with cardiac troponin T versus biochemical markers associated with cardiac remodeling. J Am Coll Cardiol, 2006; 47(Suppl.A): 324A (abstract)
58. Setsuta K, Seino Y, Ogawa T et al: Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med, 2002; 113: 717-22
59. Hansen MS, Stanton EB, Gawad Y et al: Canadian PROFILE investigators. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Am J Cardiol, 2002: 90: 969-73
60. Bhambi B, Eghbali M: Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fibroblasts after norepinephrine treatment. Am J Pathol, 1991; 139: 1131-42
61. Crabos M, Roth M, Hahn AW, Erne P: Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest, 1994; 93: 2372-78
62. Marijianowski MMH, Teeling P, Mann J, Becker AE: Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: A quatitative assessment. J Am Coll Cardiol, 1995; 25: 1263-72
63. Querejeta R, Lopez B, Gonzalez A et al: Increased collagen type I synthesis in patients with heart failure of hypertensive origin. Relation to myocardial fibrosis. Circulation, 2004; 110: 1263-68
64. Klappacher G, Franzen P, Haab D et al: Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol, 1995; 75: 913-18
65. Zannad F, Alla F, Dousset B et al: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation, 2000; 102: 2700-6.
66. Spinale FG: Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res, 2002; 90: 520-30
67. Sundstrom J, Evans JC, Benjamin EJ et al: Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J, 2004; 25: 1509-16
68. Sundstrom J, Evans JC, Benjamin EJ et al: Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures. The Framingham Heart Study. Circulation, 2004; 109: 2850-56
69. Anker SD, Ponikowski P, Varney S et al: Wasting as independent risk factor for mortality in chronic heart failure. Lancet, 1997; 349: 1050-53
70. Anker SD, Nagassa A, Coats AJS et al: Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet, 2003; 361: 1077-83
71. Anker SD, Rauchhaus M: Heart failure as a metabolic problem. Eur Heart J, 1999; 1: 127-31
72. Okonko DO, Anker SD: Anemia in chronic heart failure: Pathogenetic mechanisms. J Card Fail, 2004; 10: S5-S9
73. Sharma R, Francis DP, Pitt B et al: Haemoglobin predicts survival in patients with chronic heart failure: a susstudy of the ELITE II trial. Eur Heart J, 2004; 25: 1021-28
74. Ezekowitz JA, McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes. Insight from a cohort of 12065 patients with new-onset heart failure. Circulation, 2003; 107: 223-25
75. Anand IS, Kuskowski MA, Rector TS et al: Anemia and changes in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure. Results from Val-HeFT. Circulation, 2005; 112: 1121-27
76. Pekkanen J, Linn S, Heiss G et al: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med, 1990; 322: 1700-7
77. Horwich TB, Hamilton MA, Maclellan WR, Fanarow GC: Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail, 2002; 8: 216-24
78. Rauchhaus M, Clark AL, Doehner W et al: The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol, 2003; 42: 1933-40
79. Niebauer J, Volk HD, Kemp M et al: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet, 1999; 353: 1838-42
80. Rauchhaus M, Coats AJS, Anker SD: The endotoxin-lipoprotein hypothesis. Lancet, 2000; 356: 930-33
81. Anker SD, Doehner W, Rauchhaus M et al: Uric acid and survival in chronic heart failure. Validation and application in metabolic, functional, and hemodynamic staging. Circulation, 2003; 107: 1991-97
82. Cappola TP, Kass DA, Nelson GS et al: Allopurinol improves myocardial efficacy in patients with idiopathic dilated cardiomyopathy. Circulation, 2001; 104: 2407-11
83. Hare JM, Johnson RJ: Uric acid predicts clinical outcomes in heart failure. Insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation, 2003; 107: 1951-53
84. Shlipak MG, Massie BM: The clinical challenge of cardiorenal syndrome. Circulation, 2004; 110: 1514-17
85. Dries DL, Exner DV, Domanski MJ et al: The prognostic implications of renal insufficiency in aymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol, 2000; 35: 681-89
86. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW: Renal insufficiency and heart failure. Prognostic and therapeutic implications from a prospective cohort study. Circulation, 2004; 109: 1004-9
87. Doehner W, Rauchhaus M, Ponikowski P et al: Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol, 2005; 46: 1019-26
88. Lembo G, Capaldo B, Rendina V et al: Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am J Physiol, 1994; 266: E242-47
89. Richey JM, Ader M, Moore D, Bergman RN: Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol, 1999; 277: E920-26
90. Taylor R, Brunetti P: Molecular mechanisms of insulin resistance. Exp Clin Endocrinol Diabetes, 1999; 107: 111-12
91. Saghizadeh M, Ong JM, Garvey WT et al: The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest, 1996; 97: 1111-16
92. Mak S, Newton GE: The oxidative stress hypothesis of congestive heart failure. Chest, 2001; 120: 2035-46
93. Tsutamoto T, Wada A, Matsumoto T et al: Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol, 2001; 37: 2086-92
94. Tsutsui T, Tsutamoto T, Wada A et al: Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol, 2002; 39: 957-62
95. Garg S, Narula J, Chandrashekhar Y: Apoptosis and heart failure: clinical relevance and therapeutic target. J Mol Cell Cardiol, 2005; 38: 73-79
96. Tsutamoto T, Wada A, Maeda K et al: Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: Plasma soluble Fas as a prognostic predictor in patients with congestive heart failure. J Card Fail, 2001; 7: 322-28
97. Anand IS, Florea VG, Fisher L: Surrogate end points in heart failure. J Am Coll Cardiol, 2002; 39: 1414-21
98. McMurray J, Pfeffer MA: New therapeutic options in congestive heart failure: Part I. Circulation, 2002; 105: 2099-106
99. Benedict CR, Francis GS, Shelton B et al: Effect of long-term enelapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol, 1995; 75: 1151-57
100. Hampton JR, van Veldhuisen DJ, Kleber FX et al: Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomized Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet, 1997; 349: 971-77
101. Cohn J. Heart failure: MOXCON (Moxonidine for Congestive Heart Failure). Circulation, 1999; 100: e128
102. Latini R, Masson S, Anand I et al; Valsartan Heart Failure Trial Investigators: Effects of Valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Valsartan Heart Failure Trial (Val-HeFT). Circulation, 2002; 106: 2454-58
103. Anand IS, Fisher LD, Chiang YT et al; Val-HeFT Investigators: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation, 2003; 107: 1278-83
104. Cohn JN, Anand IS, Latini R et al; Valsartan Heart Failure Trial Investigators: Sustained reduction of aldosterone in response to the angiotensin receptor blocker Valsartan in patients with chronic heart failure. Circulation, 2003; 108: 1306-9
105. Struthers AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail, 1996; 2: 47-54
106. Latini R, Masson S, Anand I et al; For the Val-HeFT Investigators: The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J, 2004; 25: 292-99
107. Yan RT, White M, Yan AT et al; Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Investigators: Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol, 2005; 96: 698-704
108. Richards AM, Doughty R, Nicholls MG et al: Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation, 1999; 99: 786-92
109. Richards AM, Doughty R, Nicholls MG et al; Australia-New Zealand Heart Failure Group: Plasma N-terminal pro-brain natriuretic peptide and adrenomudullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Hear Failure Group. J Am Coll Cardiol, 2001; 37: 1781-87
110. Hartmann F, Packer M, Coats AJ et al: NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail, 2004; 6: 343-50
111. Luchner A, Burnett JC Jr, Jougasaki M et al: Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol, 1998; 32: 1839-44
112. White M, McKelvie RS, Hall C et al: Natriuretic peptides predict left ventricular remodeling in response to metprolol CR in patients with congestive heart failure: the RESOLVD phase II neurohumoral substudy. J Card Fail, 2001; 7(Suppl.2): 28
113. Maeda K, Tsutamoto T, Wada A et al: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol, 2000; 36: 1587-93
114. Troughton RW, Frampton CM, Yandle TG et al: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet, 2000; 355: 1126-30
115. Sato Y, Kita T, Takatsu Y, Kimura T: Biochemical markers of myocyte injury in heart failure. Heart, 2004; 90: 1110-13
116. Ishii J, Nomura M, Nakamura Y et al: Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol, 2002; 89: 691-95
117. Ishii J, Cui W, Kitagawa F et al: Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem, 2003; 49: 2020-26
118. Ralli S, Horwich TB, Fonarow GC: Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J, 2005; 150: 1220-27
119. Taniguchi R, Sato Y, Yamada T et al: Combined measurements of cardiac troponin T and N-terminal pro-brain natriuretic peptide in patients with heart failure. Circ J, 2004; 68: 1160-64
120. Taniguchi R, Sato Y, Nishio Y et al: Measurements of baseline and follow up concentrations of cardiac troponin T and brain natriuretic peptide in patients with heart failure from various etiologies. Heart Vessels, in press
121. Sato Y, Kataoka K, Matsumori A et al: Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart, 1997; 78: 505-8
122. Hunt SA, Abraham WT, Chin MH et al: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation, 2005; 112: 1825-52
123. Dzau V, Braunwald E: Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J, 1991; 121: 1244-63
124. Ridker PM, Brown NJ, Vaughan DE et al: Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation, 2004; 109(Suppl.IV): IV-6-IV19
125. Kostis JB: From hypertension to heart failure: Update on the management of systolic and diastolic dysfunction. Am J Hypertens, 2003; 16: 18S-22S
126. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA: Surrogate markers for cardiovascular disease. Functional markers. Circulation, 2004; 109(Suppl.IV): IV-31-IV-46
127. Mancini GBJ, Dahlof B, Diez J: Surrogate markers for cardiovascular disease. Circulation, 2004; 109(Suppl.IV): IV-22-IV-30
128. Lubsen J, Wagener G, Kirwan BA et al; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens, 2005; 23: 641-48
129. Blood Pressure Lowering Treatment Trialist's Collaboration. Effects of different blood -pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet, 2003; 362: 1527-35
130. Julius S, Kjeldsen SE, Mclness G: VALUE study: Outcomes in 7080 patients treated with monotherapy. J Hypertens, 2005; 23(S2): 146 (abstract)
131. Staessen JA, Wang J, Bianchi G, Birkenhager WH: Essential hypertension. Lancet, 2003; 361: 1629-41
132. Mancia G, Grassi G, Giannattasio C, Seravalle G: Sympathetic activation in the pathogesesis of hypertension and progression of organ damage. Hypertension, 1999; 34: (Part2): 724-28
133. Alderman MH, Madhavan S, Ooi WL et al: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med, 1991; 324: 1098-104
134. Goldstein DS: Plasma catecholamines and essential hypertension. An analytical review. Hypertension, 1983; 5: 86-99
135. Kaplan NM: The prognostic implications of plasma renin in essential hypertension. JAMA, 1975; 231: 167-70
136. Krum H, Viskoper RJ, Lacourciere Y et al: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med, 1998; 338: 784-90
137. Ridker PM, Rifai N, Rose L et al: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 2002; 347: 1557-65
138. Sung KC, Suh JY, Kim BS et al: High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens, 2003; 16: 429-33
139. Yasunari K, Maeda K, Watanabe T et al: Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol, 2004; 43: 2116-23
140. Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation, 2004; 110: 1103-7
141. Kohno M, Horio T, Yokokawa K et al: Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med, 1992; 92: 29-34
142. Freitag MH, Larson MG, Levy D et al: Framingham Heart Study Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. Hypertension, 2003; 41: 978-83
143. Olsen MH, Wachtell K, Tuxen C et al: N-teriminal pro-brain natriuretic peptide predicts cardiovascular events in patiets with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens, 2004; 22: 1597-604
144. Campbell DJ, Woodward M, Chalmers JP et al: Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension, 2005; 45: 69-74
145. Lopez B, Gonzalez A, Varo N et al: Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension, 2001; 38: 1222-26
146. Diez J, Laviades C, Mayor G et al: Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation, 1995; 91: 1450-56
147. Lopez B, Querejeta R, Varo N et al: Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation, 2001; 104: 286-91
148. Lindsay MM, Maxwell P, Dunn FG: TIMP-1. A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension, 2002; 40: 136-41
149. Fortuno MA, Ravassa S, Fortuno A et al: Cardiomyocyte apoptotic cell death in arterial hypertension. Mechanisms and potential management. Hypertension, 2001; 38: 1406-12
150. Siciliano M, Mettimano M, Dondolini-Poli A et al: Troponin I serum concentration: a new marker of left ventricular hypertrophy in patients with essential hypertension. Ital Heart J, 2000; 8: 532-35
151. Sato Y, Miyamoto T, Kataoka K, Takatsu Y: Biochemical markers in patients with hypertension. J Card Fail, 2005; 11(Suppl.); S314 (abstract)
152. Nieminen MS, Bohm M, Cowie MR et al; ESC Committe for Practice Guideline (CPG): Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force in Acute Heart Failure of the European Society of Cardiology. Eur Heart J, 2005; 26: 384-416
153. Sato Y, Taniguchi R, Makiyama T et al: Serum cardiac troponin T and plasma brain natriuretic peptide in patients with severe cardiac decompensation. Heart, 2002: 88: 647-48
154. Perna ER, Macin SM, Parras JI et al: Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J, 2002; 143: 814-20
155. Abraham WT, Adams KF, Fonarow GC et al; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications. An analysis from the acute decompensated heart failure national registry. (ADHERE) J Am Coll Cardiol, 2005; 46: 57-64
156. Cuffe MS, Califf RM, Adams KF Jr et al:; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators: Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA, 2002; 287: 1541-47
157. Maisel AS, Krishnaswamy P, Nowak RM et al; Breathing Not Properly Multinational Study Investigators: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med, 2002; 347: 161-67
158. Cheng V, Kazanagra R, Garcia A et al: A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol, 2001; 37: 386-91
159. Kazanegra R, Cheng V, Garcia A et al: A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail, 2001; 7: 21-29
160. Missov E, Calzolari C, Pau B: Circulating cardiac troponin I in severe congestive heart failure. Circulation, 1997; 96: 2953-58
161. Kuwabara Y, Sato Y, Miyamoto T et al: Discrepancy between the markers of myocardial load and myocyte injury measured by PATHFAST in patients with acutely decompensated heart failure. Circ J, 2006; 70(Suppl.1): 679 (abstract)
162. Miyamoto T, Sato Y, Kuwahara Y et al: The compact automated immunoassay analyzer (PATHFAST) is a useful tool for the rapid assay hematological markers in cardiovascular diseases. J Card Fail, 2005; 11(Suppl.); S314 (abstract)
163. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation, 2005; 111: 1487-91
164. Forman DE, Butler J, Wang Y et al: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol, 2004; 43: 61-67
165. Akhter MW, Aronson D, Bitar F et al: Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol, 2004; 94: 957-60
166. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH: Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation, 1981; 63: 645-51
167. Levine TB, Francis GS, Goldsmith SR et al: Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. Am J Cardiol, 1982; 49: 1659-66
168. Saito Y, Nakao K, Nishimura K et al: Clinical application of atrial natriureteic polypeptide in patients with congestive heart failure. Beneficial effects on left ventricular function. Circulation, 1987; 76: 115-24
169. Sato Y, Takatsu Y, Kataoka K et al: Serial circulating concentrations of C-reactive protein, Interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation.Clin Cardiol, 1999; 22: 811-13
170. Priori SG, Aliot E, Blomstrom-Lundqvist C et al: Task force on sudden
171. Lane RE, Cowie MR, Chow AWC: Prediction and prevention of sudden cardiac death in heart failure. Heart, 2005; 91: 674-80
172. Al-Khatib SM, Sanders GD, Mark DB et al: Expert panel participating in a Duke Clinical Research Institute-sponsored conference. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004. Am Heart J, 2005; 149: 1020-34
173. Grimm W, Christ M, Bach J et al: Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy. Results of the Marburg Cardiomyopathy Study. Circulation, 2003; 108: 2883-91
174. Madsen BK, Rasmussen V, Hansen JF: Predictors of sudden death and death from pump failure in congestive heart failure are different. Analysis of 24h Holter monitoring, clinical variables, blood chemistry, exercise test and radionuclide angiography. Int J Cardiol, 1997; 58: 151-62
175. Poole-Wilson PA, Uretsky BF, Thygesen K et al: Atlas Study Group: Assessment of treatment with lisinopril and survival. Mode of death in heart failure: findings from the ATLAS trial. Heart, 2003; 89: 42-48
176. Zipes DP, Wellens HJJ: Sudden cardiac death. Circulation, 1998; 98: 2334-51
177. Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation, 2005; 111: 3481-88
178. Albert CM, Ma J, Rifai N et al: Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation, 2002; 105: 2595-99
179. Tomasseli GF, Zipes DP: What causes sudden death in heart failure? Circ Res, 2004; 95: 754-63
180. De Mello WC: Cardiac arrhythmias: the possible role of the renin-angiotensin system. J Mol Med, 2001; 79: 103-8
181. Pacifico A, Henry PD: Structural pathways and prevention of heart failure and sudden death. J Cardiovasc Electrophysiol, 2003; 14: 764-75
182. Altschuld RA, Billman GE: β2-adrenoceptors and ventricular fibrillation. Pharmacol Therapeut, 2000; 88: 1-14
183. Cohn JN, Johnson G, Ziesche S et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med, 1991; 325: 303-10
184. Solomon SD, Wang D, Finn P et al: Effect of candesartan on cause-specifi c mortality in heart failure patients. The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program. Circulation, 2004; 110: 2180-83
185. Pitt B, Zannad F, Remme WJ et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med, 1999; 341: 709-17
186. Pitt B, Remme W, Zannad F et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med, 2003; 348: 1309-21
187. Lopez-Sendon J, Swedberg K, McMurray J et al; Task ForceOn Beta-Blockers of the European Society of Cardiology: Expert consensus document on β-adrenergic receptor blockers. Eur Heart J, 2004; 25: 1341-62
188. Berger R, Huelsman M, Strecker K et al: B-type natriuretic predicts sudden death in patients with chronic heart failure. Circulation, 2002; 105: 2392-97
189. Hansen DE, Craig CS, Hndeghem LM: Stretch-induced arrhythmias in the isolated canine ventricle: evidence for the importance of mechanoelectrical feedback. Circulation, 1990; 81: 1094-105
190. Zannad F, Dousset B, Alla F: Treatment of congestive heart failure. Interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension, 2001; 38: 1227-32
191. Zannad F, Radauceanu A: Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev, 2005; 10: 71-78